ChrysCapital earmarks up to $550m of $2.2bn fund for Indian pharma and healthcare
ChrysCapital expects to deploy 20–25% of its latest $2.2 billion fund in Indian pharma and healthcare. After acquiring Novartis India, it is bringing sales and distribution in-house while pursuing larger control deals and portfolio expansion.
What happened
ChrysCapital plans to deploy 20-25% of its $2.2 billion fund in Indian pharma and healthcare, while expanding into control deals. Following its Novartis India
Key facts
- $2.2 billion fund
- 20-25% allocation to pharma and healthcare
- $440-550 million indicative pharma allocation
- India domestic pharma market: about $60 billion in FY26
- India domestic pharma market projected at $130 billion by 2030
What changed
ChrysCapital plans to deploy 20-25% of its $2.2 billion fund in Indian pharma and healthcare, while expanding into control deals. Following its Novartis India acquisition, the drugmaker is bringing sales and distribution in-house and pursuing portfolio expansion.
Why this matters
ChrysCapital’s plan to bring Novartis India sales and distribution in-house signals a push for tighter channel control and broader healthcare portfolio expansion.
What to watch
- Announcements of a new majority acquisition, especially in chronic therapies, specialty products, consumer health, diagnostics, or hospital-linked businesses.
- Evidence that Novartis India has established its own sales force, distributor network, or direct key-account model.
- Management disclosures on sales-force productivity, distribution reach, inventory days, gross margin, and operating-cost changes at Novartis India.
- Rising transaction multiples or competitive bidding for Indian pharma control assets.
- New pharmacy-chain, hospital-network, or distributor partnerships involving ChrysCapital portfolio companies.